Brean Murray Carret & Co. Downgrades Human Genome Sciences (HGSI) to Hold; Q3 Earnings Provide Little to be Enthusiastic About

Brean Murray Carret & Co. downgraded Human Genome Sciences (NASDAQ: HGSI) from Buy to Hold.

Brean analyst says, "Benlysta sales came in at the low end of consensus expectations but in line with our own estimates. However, we believe the market will see mgmt's decision to push back the goal of profitability from 2013 to 2014 as a negative signal highlighting the company's own disappointment in the initial trajectory of Benlysta sales."

For more ratings news on Human Genome Sciences click here and for the rating history of Human Genome Sciences click here.

Shares of Human Genome Sciences closed at $12.73 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Movano (MOVE) Misses Q2 EPS by 195c
• Diana Shipping drops bid for Genco after price demands spike to $36.91